2.365

2.87% -0.075

After Hours: 2.36 -0.005 -0.21%

Immunitybio Inc (IBRX)

Overview News Price History Option Chain Financials Why IBRX Down? Discussions Forecast

Immunitybio Inc stock is traded at $2.365, with a volume of 11.39M. It is down -2.87% in the last 24 hours and down -7.78% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Previous Close:

$2.44

Open:

$2.46

24h Volume:

11.39M

Relative Volume:

1.25

Market Cap:

$2.24B

Revenue:

$1.31M

Net Income/Loss:

$-597.65M

P/E Ratio:

-2.4381

EPS:

-0.97

Net Cash Flow:

$-425.62M

1W Performance:

-6.69%

1M Performance:

-7.78%

6M Performance:

-3.66%

1Y Performance:

-26.63%

1-Day Range:

$2.36

$2.48

1-Week Range:

$2.36

$2.61

52-Week Range:

$1.83

$7.48

Immunitybio Inc Stock (IBRX) Company Profile

Name

Immunitybio Inc

Sector

Healthcare (1149)

Industry

Biotechnology (638)

Phone

(844) 696-5235

Address

3530 JOHN HOPKINS COURT, SAN DIEGO

Employee

685

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IBRX Immunitybio Inc	2.365	2.31B	1.31M	-597.65M	-425.62M	-0.97
VRTX Vertex Pharmaceuticals Inc	407.91	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.52	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.59	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	797.22	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.27	36.88B	4.56B	-176.77M	225.30M	-1.7177

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Mar-06-25	Initiated	H.C. Wainwright	Buy
Jan-10-25	Initiated	BTIG Research	Buy
May-12-23	Downgrade	Piper Sandler	Overweight → Neutral
Aug-03-22	Initiated	Jefferies	Buy

Immunitybio Inc Stock (IBRX) Latest News

01:55 AM

Will ImmunityBio Inc. rebound enough to break evenJuly 2025 Momentum & Entry and Exit Point Strategies - newser.com

01:55 AM

10:56 AM

Why ImmunityBio Inc. (26CA) stock is a strong analyst pick2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com

10:56 AM

Oct 09, 2025

Will EnGene Join The Ranks Of Merck, Ferring, And ImmunityBio In Bladder Cancer Treatment? - RTTNews

Oct 09, 2025

Will ImmunityBio Inc. stock outperform tech sector in 2025Quarterly Performance Summary & Precise Swing Trade Alerts - newser.com

Oct 09, 2025

How ImmunityBio Inc. stock reacts to job market data2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com

Oct 09, 2025

Oct 06, 2025

Real time social sentiment graph for ImmunityBio Inc.2025 Pullback Review & Accurate Intraday Trading Signals - newser.com

Oct 06, 2025

Oct 05, 2025

Evaluating ImmunityBio Inc. with trendline analysis2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com

Oct 05, 2025

Is ImmunityBio Inc. (26CA) stock prepared for digital transitionJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com

Oct 05, 2025

ImmunityBio Inc. stock retracement – recovery analysis2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com

Oct 05, 2025

Will ImmunityBio Inc. stock benefit from infrastructure spendingJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com

Oct 05, 2025

Oct 04, 2025

ANKTIVA Reimbursement Gains and UK Approval Might Change The Case For Investing In ImmunityBio (IBRX) - Sahm

Oct 04, 2025

Oct 03, 2025

ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Oct 03, 2025

What Went Wrong With ImmunityBio’s Executives Claims — and How Investors Could Still Win - TradingView

Oct 03, 2025

ImmunityBio: A Small Bet Is Warranted (NASDAQ:IBRX) - Seeking Alpha

Oct 03, 2025

NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com

Oct 03, 2025

Short interest data insights for ImmunityBio Inc.Earnings Growth Report & Technical Pattern Recognition Alerts - newser.com

Oct 03, 2025

Does ImmunityBio Inc. show high probability of reboundJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - newser.com

Oct 03, 2025

What MACD and RSI say about ImmunityBio Inc.July 2025 Retail & Weekly High Return Stock Opportunities - newser.com

Oct 03, 2025

ImmunityBio (IBRX): Revisiting Valuation After ANKTIVA’s Regulatory Wins and New Growth Initiatives - Sahm

Oct 03, 2025

Oct 02, 2025

How high can ImmunityBio Inc. stock go2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com

Oct 02, 2025

Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study - MSN

Oct 02, 2025

ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients - MSN

Oct 02, 2025

Oct 01, 2025